Q2 2025

Filed Jul 31, 2025 · 10-Q · 31 days after period end · 0000875045-25-000033

Q2 2025 · 10-Q

Revenue

$2.65B

+7.3% vs Q2 2024

Net Income

$634.80M

+8.8% vs Q2 2024

EPS Diluted

$4.33

+8.3% vs Q2 2024

Operating Cash Flowderived$160,900,000−74.3%

Same quarter

Metric	Q2 2025	Q2 2024	Q2 2023	Q2 2020
Revenue	$2.65B	$2.46B	$2.46B	$3.68B
Net Income	$634.80M	$583.60M	$591.60M	$1.54B
EPS Diluted	$4.33	$4.00	$4.07	$9.59

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Biogen Inc. · CIK 875045 · Engraved from SEC EDGAR